Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 445
- Registration Number
- NCT02242942
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT02240355
- Locations
- 🇫🇷
Ch Pitie Salpetriere; Institut de Myologie, Paris, France
🇸🇪Drottning Silvias Barn- och ungdomssjukhus; Kliniken för barnmedicin, Goeteborg, Sweden
🇹🇷Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit, Ankara, Turkey
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
- Conditions
- Lymphoma, B-Cell, Lymphoma, Follicular
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 688
- Registration Number
- NCT02240316
- Locations
- 🇩🇪
Universitätsklinikum Essen; Klinik für Hämatologie, Essen, Germany
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis
- Conditions
- Chronic Kidney Diseases
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 197
- Registration Number
- NCT02238080
- Locations
- 🇮🇱
Holy Family Hospital; Nephrology, Nazareth, Israel
🇮🇱Rebecca Sief Hospital; Nephrology, Safed, Israel
🇮🇱Sourasky MC; Dept. of Nephrology, Tel Aviv, Israel
Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
- Conditions
- Chronic Kidney Diseases
- Interventions
- Drug: ESAOther: Satisfaction Survey Questionnaire
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 196
- Registration Number
- NCT02238067
- Locations
- 🇮🇱
Clalit- New Savyon Clinic, Ganey Tikva, Israel
🇮🇱Kaplan Medical Center; Nephrology and Hypertension Services, Rehovot, Israel
🇮🇱Clalit - Diabetic HaMoshava South Clinic, Jerusalem, Israel
Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT02234960
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT02220842
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷Hôpital Saint-Louis, Paris, France
A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Placebo RD + AVP SDDrug: RG7314 RD + AVP SDDrug: Placebo RD + Placebo SD
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT02205073
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02204345
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02201407
- Locations
- 🇷🇸
Clinical Center Zemun, Belgrade, Serbia
🇷🇸Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
🇷🇸Clinical Center Vojvodine; Clinic for Infectious Diseases; Clinic for Hematology, Novi Sad, Serbia